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Abstract 8 
 9 
Objectives 10 
To compare the recognised Defined Daily Dose per 100 bedday measure (DDD/100 11 
bedday) with the Defined Daily Dose per Finished Consultant Episode (DDD/FCE) in 12 
a group of hospitals with a variety of medicines management strategies.  13 
To compare antibiotic usage using the above indicators in hospitals with and without 14 
electronic prescribing systems.  15 
 16 
Methods 17 
Twelve hospitals were used in the study. Nine hospitals were selected and split into 18 
three cohorts (three high-scoring, three medium-scoring and three low-scoring) by 19 
their 2001 Medicines Management self-assessment scores (MMAS). An additional 20 
cohort of three electronic prescribing hospitals was included for comparison. MMAS 21 
were compared to Antibiotic Management Scores (AMS) developed from a 22 
questionnaire relating specifically to control of antibiotics. FCEs and occupied 23 
beddays were obtained from published statistics and statistical analysis of the 24 
DDD/100 beddays and DDD/FCE were carried out using SPSS. 25 
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 1 
Results 2 
The DDD/100 beddays varied from 81.33 to 189.37 whilst the DDD/FCE varied from 3 
2.88 to 7.43. The two indicators showed a high degree of correlation r = 0.74. 4 
MMAS were from 9 to 22 (possible range 0 to 23) and the AMS from 2 to 13 5 
(possible range 0 to 22). The two scores showed a high degree of correlation r = 0.74. 6 
No correlation was established between either indicator and either score. 7 
 8 
Conclusions 9 
The WHO indicator for medicines utilisation, DDD/100 beddays, exhibited the same 10 
level of conformity as that exhibited from the use of the DDD/FCE indicating that the 11 
DDD/FCE is a useful additional indicator for identifying hospitals which require 12 
further study.  13 
 14 
The MMAS can be assumed to be an accurate guide to antibiotic medicines 15 
management controls. 16 
 17 
No relationship has been found between a high degree of medicines management 18 
control and the quantity of antibiotic prescribed. 19 
 20 
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Introduction 1 
It has been estimated1 that twenty per cent of medicines expenditure in England 2 
occurs in secondary care. However, there is little aggregated data relating to the use of 3 
medicines in this sector. Pilot work,2 found that during the period between January 4 
1997 and December 1998, antibiotics accounted for nineteen per cent of the total 5 
expenditure on medicines in secondary care, which was the highest spend of all 6 
categories of medicinal product. Participants within the study also highlighted that 7 
there was a need for a suitable indicator to facilitate benchmarking between hospitals.  8 
 9 
The emergence of ‘evidence based practice’ during the NHS policy reforms of the 10 
1990s was part of the change to create a culture in which clinical governance drives 11 
individual hospital practitioners to examine their practice and compare it with their 12 
peers. Pharmaceutical care, ‘the responsible provision of drug therapy for the purpose 13 
of achieving definite outcomes that improve a patient’s quality of life’3 defines the 14 
scope of pharmaceutical responsibility in the use of medicines. This was 15 
supplemented by the ‘medicines management’ concept,4 which developed the theme 16 
of systems to control medicines usage from procurement, managed entry onto a 17 
hospital formulary through to prescribing review and use of clinical guidelines. In 18 
order to optimise the use of medicines, it is vital that therapeutic categories of 19 
medicines where there is high-volume and high-cost are reviewed. It has been 20 
established that antibiotics are often both high-volume and high-cost. In addition, it 21 
has been demonstrated5 that a large percentage of antibiotic use in hospitals is 22 
inappropriate.  23 
 24 
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Clearly, there is a requirement for multi-centre clinical audit of antibiotic usage. 1 
However, in order to benchmark the use of antibiotics across the full spectrum of 2 
secondary care settings, a robust measure is needed which is independent of 3 
workload, in order that comparisons can be made. The UK Department of Health has 4 
recently allocated funding for each English hospital to use for promoting ‘prudent use 5 
of antibiotics’.6 This initiative will enable work to commence to improve targeted 6 
clinical pharmacy initiatives related to antibiotic use and also to begin to address 7 
collection of data from hospitals. 8 
 9 
A large amount of therapeutic guidance7-12 has been published, which focuses on 10 
antibiotic resistance and the use of antibiotics in medicine. Issues examined include 11 
the use of formularies within hospitals, the process by which antibiotics are prescribed 12 
by junior doctors, sensitivity testing and the surveillance of resistant organisms. One 13 
report13 concluded that there was a lack of data on antimicrobial use in hospitals and 14 
that hospitals should install computerised systems for patient specific prescribing.  15 
 16 
The European Society for Clinical Microbiology and Infectious Disease (ESCMID) 17 
established a study group on antibiotic policies (ESGAP) which in turn created a 18 
number of sub-groups to develop strategy related to the stewardship of antibiotics 19 
within European hospitals. This group produced a number of recommendations14 20 
which include a commendation that ‘measurement of antibiotic consumption should 21 
be performed with regular benchmarking of figures and discussion between 22 
prescribers, pharmacists and infection specialists’. 23 
 24 
Antibiotic prescribing indicators 
 5
The purpose of any indicator of prescribing is to enable comparisons to be made over 1 
time. The comparison may be between individual prescribers, wards, specialties, 2 
hospitals or geographical groups of hospitals. Measures are not definitive but act as a 3 
focus for the commencement of review and should act as a stimulus for change.  4 
 5 
The need for an international classification system for drugs has been recognised for 6 
many years.15 The Anatomical Therapeutic Chemical System (ATC), was developed 7 
by the Norwegian Medicinal Depot, in Oslo, by modification of an existing system 8 
that had been used by pharmaceutical market researchers in Europe. In addition to a 9 
robust classification system it was necessary to develop a unit of measurement. The 10 
Defined Daily Dose (DDD) was developed, also by the Norwegian Medicinal Depot 11 
as a unit of measurement for use in drug utilisation studies. The ATC/DDD system, 12 
was recommended for international drug utilisation studies by the World Health 13 
Organisation (WHO) in 1981. The purpose of the ATC/DDD system is to act as a tool 14 
for drug utilisation research so that the quality of drug usage will improve. 15 
 16 
The DDD is defined16 as ‘the assumed average maintenance dose per day for a drug 17 
used for its main indication in adults’. A DDD is only assigned when a compound has 18 
been given an ATC code. All of the ATC codes and DDD data are published in the 19 
ATC Index.17 The DDD is not a reflection of a prescribed or recommended daily 20 
dose. It represents a unit of measurement to enable researchers to identify trends in 21 
consumption of medicines and to compare the exposure to specific medicines of 22 
population groups. The DDD is a compromise in that it is based on a review of doses 23 
used in a variety of countries. The DDD will normally be associated with a 24 
Antibiotic prescribing indicators 
 6
denominator to correct for workload variations. For hospital in-patients the number of 1 
DDDs per 100 beddays is normally used.  2 
 3 
A study of the DDD system18 compared the approach of Europeans to undertaking 4 
drug utilisation review with that of the North Americans which has focussed more on 5 
review of individual prescribers and individual drug regimens in order to optimise 6 
patient treatments.  7 
 8 
This study concluded that the DDD system would serve as a valuable additional tool 9 
for drug utilisation studies. A further study carried out to evaluate DDD 10 
methodology19 concluded that calculation of the DDD was a valuable first step in 11 
measuring total drug use in a population, but that for more precise estimates of drug 12 
use, other techniques would also be required. 13 
 14 
An antibiotic usage measure developed in 1998 within our group20 has been applied 15 
previously to the usage of quinolone antibiotics. In order to more fully evaluate the 16 
usefulness of this measure as a tool to compare antibiotic utilisation, the present study 17 
compares the recognised DDD/100 bedday measure with the DDD/FCE in a group of 18 
hospitals with a variety of medicines management strategies.  19 
 20 
Materials and method 21 
Four cohorts of three hospitals were used as data collection sites. These hospitals were 22 
selected for their differing inter-group characteristics, in terms of size, workload, 23 
case-mix and medicines management strategy. The sample size was 6.65% of hospital 24 
activity in England based on the total number of FCEs completed in the year 2001/2 25 
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(822,445 FCEs from a total of 12,357,360; data obtained from Hospital Episode 1 
Statistics 2001/2 Department of Health, London). A Finished Consultant Episode 2 
(FCE) being defined as ‘a period of healthcare under one Consultant, in one hospital 3 
provider’.21 4 
 5 
Antibiotic usage data was collected for systemic antibacterials (ATC category J01). 6 
 7 
The number of occupied beddays and FCEs for each Trust for 2001/2 was recorded 8 
from the Department of Health published Hospital Episode Statistics. 9 
 10 
The hospitals were selected on the basis of their medicines management self-11 
assessment scores arising from a nationally sponsored self-assessment exercise carried 12 
out at the beginning of 2001.22 This self-assessment consisted of six equally weighted 13 
domains of activity related to medicines management, with a high score being 14 
indicative of a high degree of control of medicines usage. The maximum possible 15 
aggregate score was 23. The six-domains were as follows – 16 
 Senior management awareness and involvement 17 
 Information and financial issues 18 
 Medicines policy management, including the introduction of new drugs 19 
 Procurement of medicines 20 
 The primary and secondary care interface 21 
 Influencing prescribers 22 
 23 
It was felt that the scores from this exercise would be indicative of the degree of 24 
control and influence over the general use of medicines and more specifically, 25 
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antibiotics, and that high scores in this measure would be linked to low levels of 1 
antibiotic usage (divergent validity). 2 
 3 
Reviewing the scores for hospitals in the West Midlands, it was possible to select 4 
three high-scoring hospitals (score >19), together with three medium scoring hospitals 5 
(score >15 but < 19) and a third group with lower scores (score <15).  6 
 7 
In addition, to these nine hospitals it was felt that the three English hospitals that have 8 
fully implemented electronic prescribing systems would be used as a discrete 9 
comparator reflecting the potential importance of electronic prescribing systems in 10 
controlling medicines usage. The characteristics of the hospital trusts participating in 11 
the present study are summarised in Table 1. 12 
 13 
In order to validate the medicines management scores which relate to general control 14 
systems in place for all medicines, a questionnaire was designed containing questions 15 
covering 11 aspects of medicines management relating specifically to control of the 16 
use of antibiotics. This ensured consistency in interpretation of the questions across 17 
the sample. The data generated from the questionnaire would also support and cross-18 
reference the results from the medicines management self-assessment tool. The 19 
questions covered areas of recognised good practice in control of antibiotic usage and 20 
included – audit of usage, data sharing between pharmacy and microbiology 21 
departments, liaison with Infection Control services, pharmacy led educational 22 
initiatives, pharmacist empowerment to convert from IV to oral routes, pharmacist 23 
discontinuation of therapy and rationalisation of formulary choices of antibiotics.  24 
The maximum possible score for this assessment was 22. 25 
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Statistical treatments 1 
Data was entered into a flatfield database and analysed using the SPSS version 11 2 
software package.  3 
 4 
Results 5 
Table 2 lists each Trust included in the present study with details of activity, the total 6 
number of DDDs of antibiotic used in 2001/2 and the derived prescribing indicators 7 
and Medicines Management scores. 8 
 9 
The range of Medicines Management scores was from 9 to 22 and the Antibiotic 10 
Management Scores ranged from 2 to 13. The DDD/100 beddays varied from 81.33 to 11 
189.37 (mean 114.62). The DDD/FCE varied from 2.88 to 7.43 (mean 4.1). 12 
 13 
Figure 1 shows the correlation of the two prescribing indicators (Pearson correlation r 14 
= 0.74). Figure 2 shows the correlation of the medicines management scores (Pearson 15 
correlation r = 0.74). 16 
17 
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Discussion 1 
The present study has evaluated the performance of two prescribing indicators, one 2 
established, the other experimental, in assessing antibiotic prescribing in a range of 3 
UK hospital trusts. The DDD/FCE and DDD/100 bedday results did show a 4 
significant correlation (r = 0.74). It was felt that this demonstrated the robustness of 5 
the proposed indicator as an additional measure for use when antibiotic drug 6 
utilisation studies are being carried out. This in turn facilitates the identification of 7 
hospitals where more detailed or specialised analysis of antibiotic prescribing is 8 
required. 9 
 10 
The electronic prescribing group had the lowest mean usage 3.5 DDD/FCE. It is likely 11 
that the use of a computerised prescribing system enhances good practice in 12 
prescribing by allowing pre-agreed ‘stop dates’ to be programmed together with 13 
reminders about reviewing treatment and by providing a greater degree of formulary 14 
control. It would be valuable for a prospective study to be carried out to establish 15 
whether this is the case. 16 
 17 
The total antibiotic usage figures for the twelve hospitals varied from 81.33 – 189.37 18 
DDD/100 beddays (mean 114.6). These findings can be compared with data from 19 
various European studies which found usage at 37.2 – 42.5,23 41 – 5124 and 25-68. 25  20 
It may be that the much higher rates of antibiotic usage found in this study reflect a 21 
difference in the categories of patients that are included in secondary care activity data 22 
and how the English health care system operates. 23 
 24 
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The results do not show an association between a high score in either of the medicines 1 
management scores and a low value for the two prescribing indicators of antibiotic 2 
usage (Table 2). This lack of relationship leads to a conclusion that enhancing 3 
medicines management controls may not reduce antibiotic prescribing. These findings 4 
may indicate that antibiotic prescribing patterns within the study hospitals are subject 5 
to influences not embraced by the indicators employed. Such factors may include the 6 
morbidity of the hospital’s catchment population, the casemix of patients treated, 7 
which in turn will be governed by the service profile offered by each hospital in terms 8 
of specialties and number of beds devoted to each specialty. 9 
 10 
A morbidity profile for the catchment population of an individual hospital can be 11 
created from analysis of the Primary Care Trust of residence of patients treated and 12 
linking this to morbidity measures obtained from census data. This work is on-going. 13 
The influence of casemix will influence the WHO measure (DDD/100 beddays) to a 14 
greater degree than the DDD/FCE, since variations in casemix e.g. more surgical 15 
beds, would decrease the average length of stay within a hospital, whilst conversely a 16 
greater proportion of Care of the Elderly beds will generally increase the average 17 
length of stay.  18 
 19 
The FCE is more closely linked to individual in-patient exposure rates to antibiotics 20 
than bedday numbers, as it is a measure of episodes of individual care. However, in 21 
some cases the episode of care may involve a number of Consultants that can lead to 22 
it being counted as more than one FCE. 23 
 24 
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It is apparent that additional data is needed before conclusions about the quality of 1 
antibiotic usage in a specific hospital can be drawn. The specific profile of antibiotic 2 
use by therapeutic group for each hospital, together with local bacterial resistance 3 
data, would provide valuable comparative data. This will need to be linked to 4 
morbidity data and the usage data linked to activity will require monitoring over a 5 
number of years in order to determine the effects of controls systems, be they 6 
electronic prescribing systems, utilisation of pharmacists with a remit to change 7 
antibiotic prescribing habits or the establishment of multidisciplinary review teams. In 8 
order to maximise the opportunity for change to occur pharmacists will need to work 9 
closely with microbiologists to influence prescribing habits. 10 
 11 
The Medicines Management self-assessment score (MMAS) and the Antibiotic 12 
Medicines Management score (AMS) showed a high degree of correlation (r = 0.74), 13 
which demonstrates that the MMAS is a valid indicator of antibiotic medicines 14 
management arrangements.  15 
16 
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Conclusion 1 
The WHO indicator for medicines utilisation, DDD/100 beddays, showed the same 2 
level of conformity which was exhibited from the use of the DDD/FCE (r = 0.74) 3 
indicating that the DDD/FCE is a useful indicator for identifying hospitals which 4 
require further study.  5 
The present study has highlighted the following points: 6 
 7 
 It is proposed that both the DDD/100beddays and the DDD/FCE are used to 8 
compare antibiotic usage between hospitals in England.  9 
 The electronic prescribing cohort showed the lowest level of usage 10 
(DDD/FCE) which may indicate the value of computerised prescribing 11 
systems in promoting appropriate antibiotic prescribing. 12 
 Medicines Management measures are only a single contributor to a hospitals 13 
antibiotic usage profile and may influence quality but not quantity of 14 
antibiotic prescribed. 15 
 Further work over a number of years is required to establish trends to validate 16 
these results.  17 
 18 
19 
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Table 1. Hospital sites included in the present study 
Hospital Comment 
Number 
of beds 
Cohort 
1  Urban acute trust 1347 A 
2  Urban acute trust 1330 A 
3  Urban acute trust 811 A 
4  Small town, electronic prescribing 465 B 
5  Suburban, electronic prescribing 1279 B 
6  County town, electronic prescribing 569 B 
7  Urban acute trust 956 C 
8  Urban trust 634 C 
9 
 Urban trust 
(with infectious disease unit) 
1320 C 
10  Suburban trust 503 D 
11  Specialist trust 227 D 
12  County town 630 D 
 
Cohort A Medicines Management self assessment score (MMAS) >19 
Cohort B Electronic prescribing site 
Cohort C Medicines Management self assessment score (MMAS) >15 & <19 
Cohort D Medicines management self assessment score (MMAS) <15 
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Table 2. Summary data 2001/2 
H
os
pi
ta
l 
(c
oh
or
t)
 
FCEs Beddays DDDs DDD/ 100beddays 
DDD/
FCE 
Medicines 
Management 
score 
(max 23) 
Antibiotic 
management 
score 
(max 22) 
1 (A) 93626 376259 413011 109.76 4.41 20 6 
2 (A) 124357 339618 403806 118.9 3.24 20 11 
3 (A) 72193 203178 330315 162.57 4.57 19.5 11 
4 (B) 48047 142560 185511 130.1 3.86 16 11 
5 (B) 97215 373071 328851 88.14 3.38 22 13 
6 (B) 45225 166047 152055 91.57 3.35 16 4 
7 (C) 66845 263099 268607 102.09 4.01 17.5 8 
8 (C)  49856 186924 173368 92.74 3.47 17 6 
9 (C) 103607 406430 769661 189.37 7.43 16 3 
10 (D) 54963 176542 158421 89.73 2.88 14 7 
11 (D) 8984 52906 43032 81.33 4.79 9 2 
12 (D) 53192 173265 206543 119.2 3.88 13 3 
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Figure 1. DDD/100 beddays vs DDD/FCE 
Figure 1. DDD/100 beddays vs DDD/FCE
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Pearson correlation r = 0.74. 
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Figure 2. MMAS vs AMS 
Figure 2. MMAS vs AMS
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Pearson correlation r = 0.74. 
 
